Sentinel-node biopsy in melanoma [7]

New England Journal of Medicine

Volumn 356, Issue 4, 2007, Pages 419-

  Retsas, Spyros ^a  

^a CROMWELL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LETTER; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MELANOMA; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME; LYMPH NODE METASTASIS; METASTASIS; NOTE; PATHOLOGY; PROGNOSIS; SKIN TUMOR;

HUMANS; LYMPHATIC METASTASIS; MELANOMA; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 33846436422     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
2. Retsas S. Cutaneous melanoma. Lancet 2005;365:2003-4.
3. Retsas S, Henry K, Mohammed MQ, MacRae K. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. Eur J Cancer 2002;38:511-6.